Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Prudential PLC (PUK) Price & Performance

AbCellera Biologics IncTrade
Prudential PLCTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Prudential PLC — how do they compare? AbCellera Biologics Inc trades at $9.09 (market cap $2.85B), while Prudential PLC trades at $27.46 (market cap $34.98B). The key difference: Prudential PLC is far larger — about 12.3× AbCellera Biologics Inc's market cap, and Prudential PLC pays a 1.89% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLPUK
Market Cap
$2.85B$34.98B
Sector
HealthFinancials
52-Week High
$9.76$33.61
52-Week Low
$2.78$24.98
Enterprise Value
$2.45B$36.41B
Dividend Yield
1.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

Prudential PLC

Prudential Financial (PUK) trades at $28.28, up 1.43% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with Q2 2025 and Q4 2025 earnings beats, robust 14.52% net income margin, and improving cash flow trends. Recent news highlights China regulatory concerns impacting Asian-focused insurers, though Prudential reported solid Q2 2026 results with $985 million net income.

The stock presents value characteristics with a low P/E of 9.21, supported by analyst consensus leaning bullish (50% buy ratings). Key risks include China regulatory exposure and competitive pressures in Asian markets. Upside potential exists if the company successfully executes its capital-light strategy and navigates geopolitical challenges.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Prudential PLC

Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.

Read more on PUK